flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

V-Bio Ventures invests in RootWave in a EUR 6.5 m Series A financing to develop and market electrical weed killing solutions

Today V-Bio Ventures announces its investment in RootWave, a pioneer in electrical weed killing solutions. RootWave secured ca. EUR 6.5m in a Series A investment round led by V-Bio Ventures (Belgium) and Rabo Food & Agri Innovation Fund (Netherlands), and joined by impact fund Pymwymic (Netherlands) and existing shareholders including Yield Lab Ireland. The proceeds will enable RootWave to expand commercialisation of its RootWave Pro, a professional hand-weeder for spot weeding and treating invasive species, integrate its technology into automated agricultural weeders, and conduct further research into novel electricity-based weed killing applications.

Finance | 20 January 20
Read more
20
Jan
2020

V-Bio Ventures invests in RootWave in a EUR 6.5 m Series A financing to develop and market electrical weed killing solutions

Today V-Bio Ventures announces its investment in RootWave, a pioneer in electrical weed killing solutions. RootWave secured ca. EUR 6.5m in a Series A investment round led by V-Bio Ventures (Belgium) and Rabo Food & Agri Innovation Fund (Netherlands), and joined by impact fund Pymwymic (Netherlands) and existing shareholders including Yield Lab Ireland. The proceeds will enable RootWave to expand commercialisation of its RootWave Pro, a professional hand-weeder for spot weeding and treating invasive species, integrate its technology into automated agricultural weeders, and conduct further research into novel electricity-based weed killing applications.

15
Jan
2020

Fibrocor and Galapagos sign expanded collaboration in fibrosis

Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor.

13
Jan
2020

Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis

Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the PINTA Phase 2 clinical trial with oral GPR84 inhibitor GLPG1205.

13
Jan
2020

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of the next-generation, NKG2D-based candidate CYAD-02 to a relapsed/refractory acute myeloid leukemia (r/r AML) patient enrolled in the Phase 1 CYCLE-1 trial.

13
Jan
2020

Imec ontwikkelt proces voor volumeproductie van microchip voor synthetisch DNA

EVONETIX LTD ('Evonetix'), dat een desktoptoestel voor DNA-synthese ontwikkelt op basis van een vernieuwende microchip, kondigde vandaag aan dat het samenwerkt met imec, ‘s werelds toonaangevende onderzoeks- en innovatiehub op het vlak van nano-elektronica en digitale technologie. Samen zullen ze het productieproces van de unieke microchips opschalen om het DNA-synthesetoestel van Evonetix op commerciële schaal te kunnen produceren. Het toestel zal een belangrijke vooruitgang betekenen in het snel groeiende domein van de synthetische biologie.

20
Jan
2020

V-Bio Ventures invests in RootWave in a EUR 6.5 m Series A financing to develop and market electrical weed killing solutions

Today V-Bio Ventures announces its investment in RootWave, a pioneer in electrical weed killing solutions. RootWave secured ca. EUR 6.5m in a Series A investment round led by V-Bio Ventures (Belgium) and Rabo Food & Agri Innovation Fund (Netherlands), and joined by impact fund Pymwymic (Netherlands) and existing shareholders including Yield Lab Ireland. The proceeds will enable RootWave to expand commercialisation of its RootWave Pro, a professional hand-weeder for spot weeding and treating invasive species, integrate its technology into automated agricultural weeders, and conduct further research into novel electricity-based weed killing applications.

15
Jan
2020

Fibrocor and Galapagos sign expanded collaboration in fibrosis

Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor.

13
Jan
2020

Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis

Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the PINTA Phase 2 clinical trial with oral GPR84 inhibitor GLPG1205.

13
Jan
2020

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of the next-generation, NKG2D-based candidate CYAD-02 to a relapsed/refractory acute myeloid leukemia (r/r AML) patient enrolled in the Phase 1 CYCLE-1 trial.

13
Jan
2020

Imec ontwikkelt proces voor volumeproductie van microchip voor synthetisch DNA

EVONETIX LTD ('Evonetix'), dat een desktoptoestel voor DNA-synthese ontwikkelt op basis van een vernieuwende microchip, kondigde vandaag aan dat het samenwerkt met imec, ‘s werelds toonaangevende onderzoeks- en innovatiehub op het vlak van nano-elektronica en digitale technologie. Samen zullen ze het productieproces van de unieke microchips opschalen om het DNA-synthesetoestel van Evonetix op commerciële schaal te kunnen produceren. Het toestel zal een belangrijke vooruitgang betekenen in het snel groeiende domein van de synthetische biologie.

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?